ISRCTN86885538 https://doi.org/10.1186/ISRCTN86885538

Taurolidine-citrate vs heparin as catheter lock solutions in paediatric patients

Submission date	Recruitment status	[_] Prospectively registered
07/12/2006	No longer recruiting	[_] Protocol
Registration date	**Overall study status**	[_] Statistical analysis plan
16/01/2007	Completed	[_] Results
Last Edited	**Condition category**	[_] Individual participant data
08/02/2011	Infections and Infestations	[_] Record updated in last year

Plain English summary of protocol
Not provided at time of registration

Contact information

Type(s)
Scientific

Contact name
Prof Uwe Querfeld

Contact details
Department of Pediatric Nephrology
Charité Universitätsmedizin Berlin
Berlin
Germany
13353

Additional identifiers

EudraCT/CTIS number

IRAS number

ClinicalTrials.gov number

Secondary identifying numbers
EA2/084/06

Study information

Scientific Title

Acronym
Taurolock study

Study objectives
Use of taurolidine-citrate for catheter locking leads to a significant reduction of bacterial growth and catheter-related infections in paediatric patients with implanted central venous catheters

Ethics approval required
Old ethics approval format

Ethics approval(s)
Approval received by local ethics committee (Ethikkommission 2 am Campus Virchow Klinikum) on 29 September 2006 (ref: EA2/084/06).

Study design
Randomized prospective study in pediatric hospital with stratification for patients treated in renal/oncology/hematology departments

Primary study design
Interventional

Secondary study design
Randomised controlled trial

Study setting(s)
Not specified

Study type(s)
Not Specified

Participant information sheet

Health condition(s) or problem(s) studied
Catheter-related infections

Interventions
Taurolidine-citrate vs heparin as catheter lock solutions

Intervention Type
Other

Phase
Not Specified

Primary outcome measure
Bacterial growth/biofilm formation in removed catheters

Secondary outcome measures

Catheter-related infections, catheter occlusions

Overall study start date
01/01/2007

Completion date
31/12/2007

Eligibility

Key inclusion criteria
Paediatric patients with newly implanted central venous catheters

Participant type(s)
Patient

Age group
Child

Sex
Not Specified

Target number of participants
100

Key exclusion criteria
Bacteremia/sepsis ongoing; allergy against heparin or taurolidine

Date of first enrolment
01/01/2007

Date of final enrolment
31/12/2007

Locations

Countries of recruitment
Germany

Study participating centre
Department of Pediatric Nephrology
Berlin
Germany
13353

Sponsor information

Organisation
Tauropharm (Germany)

Sponsor details
Jägerstraße 5a
97297
Waldbüttelbrunn
Germany
97297

Sponsor type
Industry

Funder(s)

Funder type
Industry

Funder Name
Tauropharm GmbH (Germany)

Results and Publications

Publication and dissemination plan
Not provided at time of registration

Intention to publish date

Individual participant data (IPD) sharing plan

IPD sharing plan summary
Not provided at time of registration